A role for CD20 antibodies in treating prostate cancer has not yet been established.
We report a case of advanced prostate cancer presenting with generalized lymphadenopathy that expressed CCR7 and CD20. CCR7 expression in prostate cancer has been previously reported only once; the expression of CD20 has not been reported before. Rituximab therapy was initiated in this case and resulted in a significant biochemical response. This unique metastatic and biochemical pattern may signify a distinct subtype of prostate cancer that may be amenable to treatment with anti-CD20 antibodies.
Written by:
Dalgleish A, Featherstone P, Vlassov V, Rogosnitzky M. Are you the author?
Division of Clinical Sciences, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK.
Reference: Invest New Drugs. 2014 Jan 18. Epub ahead of print.
doi: 10.1007/s10637-014-0063-z
PubMed Abstract
PMID: 24442368
UroToday.com Prostate Cancer Section
